Literature DB >> 16813737

Modifications of coronary risk factors.

Jeanine Albu1, Sheldon H Gottlieb, Phyllis August, Richard W Nesto, Trevor J Orchard.   

Abstract

In addition to the revascularization and glycemic management interventions assigned at random, the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) design includes the uniform control of major coronary artery disease risk factors, including dyslipidemia, hypertension, smoking, central obesity, and sedentary lifestyle. Target levels for risk factors were adjusted throughout the trial to comply with changes in recommended clinical practice guidelines. At present, the goals are low-density lipoprotein cholesterol <2.59 mmol/L (<100 mg/dL) with an optional goal of <1.81 mmol/L (<70 mg/dL); plasma triglyceride level <1.70 mmol/L (<150 mg/dL); blood pressure level <130 mm Hg systolic and <80 mm Hg diastolic; and smoking cessation treatment for all active smokers. Algorithms were developed for the pharmacologic management of dyslipidemia and hypertension. Dietary prescriptions for the management of glycemia, plasma lipid profiles, and blood pressure levels were adapted from existing clinical practice guidelines. Patients with a body mass index >25 were prescribed moderate caloric restriction; after the trial was under way, a lifestyle weight-management program was instituted. All patients were formally prescribed both endurance and resistance/flexibility exercises, individually adapted to their level of disability and fitness. Pedometers were distributed as a biofeedback strategy. Strategies to achieve the goals for risk factors were designed by BARI 2D working groups (lipid, cardiovascular and hypertension, and nonpharmacologic intervention) and the ongoing implementation of the strategies is monitored by lipid, hypertension, and lifestyle intervention management centers.

Entities:  

Mesh:

Year:  2006        PMID: 16813737      PMCID: PMC2670550          DOI: 10.1016/j.amjcard.2006.03.012

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  59 in total

1.  Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition.

Authors:  Temduang Chuahirun; Donald E Wesson
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Cigarette smoking and glycaemia: the EPIC-Norfolk Study. European Prospective Investigation into Cancer.

Authors:  L A Sargeant; K T Khaw; S Bingham; N E Day; R N Luben; S Oakes; A Welch; N J Wareham
Journal:  Int J Epidemiol       Date:  2001-06       Impact factor: 7.196

3.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.

Authors:  F M Sacks; L P Svetkey; W M Vollmer; L J Appel; G A Bray; D Harsha; E Obarzanek; P R Conlin; E R Miller; D G Simons-Morton; N Karanja; P H Lin
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

4.  Current recommendations for the treatment of hypertension: are they still valid?

Authors:  Marvin Moser
Journal:  J Hypertens Suppl       Date:  2002-02

5.  The Diabetes Prevention Program (DPP): description of lifestyle intervention.

Authors: 
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

6.  UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes.

Authors:  Amanda I Adler; Richard J Stevens; Andrew Neil; Irene M Stratton; Andrew J M Boulton; Rury R Holman
Journal:  Diabetes Care       Date:  2002-05       Impact factor: 19.112

7.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

Authors: 
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

8.  UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.

Authors:  Viti Kothari; Richard J Stevens; Amanda I Adler; Irene M Stratton; Susan E Manley; H Andrew Neil; Rudy R Holman
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

9.  Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus.

Authors:  A Garg; J P Bantle; R R Henry; A M Coulston; K A Griver; S K Raatz; L Brinkley; Y D Chen; S M Grundy; B A Huet
Journal:  JAMA       Date:  1994-05-11       Impact factor: 56.272

Review 10.  The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.

Authors:  Maria-Teresa Zanella; Artur B Ribeiro
Journal:  Clin Ther       Date:  2002-07       Impact factor: 3.393

View more
  9 in total

1.  Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial.

Authors:  Vera Bittner; Marnie Bertolet; Rafael Barraza Felix; Michael E Farkouh; Suzanne Goldberg; Kodangudi B Ramanathan; J Bruce Redmon; Laurence Sperling; Martin K Rutter
Journal:  J Am Coll Cardiol       Date:  2015-08-18       Impact factor: 24.094

2.  Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  Maria Mori Brooks; Sheng-Chia Chung; Tarek Helmy; William B Hillegass; Jorge Escobedo; Kathryn A Melsop; Elaine M Massaro; Robert D McBane; Pamela Hyde; Mark A Hlatky
Journal:  Circulation       Date:  2010-10-11       Impact factor: 29.690

3.  Appropriate revascularization in stable angina: lessons from the BARI 2D trial.

Authors:  Ronald J Krone; Andrew D Althouse; Jacqueline Tamis-Holland; Lakshmi Venkitachalam; Arturo Campos; Alan Forker; Alice K Jacobs; Salvador Ocampo; George Steiner; Francisco Fuentes; Ivan R Pena Sing; Maria Mori Brooks
Journal:  Can J Cardiol       Date:  2014-08-20       Impact factor: 5.223

4.  Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors: 
Journal:  Am Heart J       Date:  2008-07-31       Impact factor: 4.749

5.  Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Maria Mori Brooks; Bernard R Chaitman; Richard W Nesto; Regina M Hardison; Frederick Feit; Bernard J Gersh; Ronald J Krone; Edward Y Sako; William J Rogers; Alan J Garber; Spencer B King; Charles J Davidson; Fumiaki Ikeno; Robert L Frye
Journal:  Circulation       Date:  2012-09-24       Impact factor: 29.690

6.  Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Jeanine B Albu; Jiang Lu; Arshag D Mooradian; Ronald J Krone; Richard W Nesto; Marty H Porter; Jamal S Rana; William J Rogers; Burton E Sobel; Sheldon H Gottlieb
Journal:  Obesity (Silver Spring)       Date:  2009-10-29       Impact factor: 5.002

7.  Race/ethnic disparities in risk factor control and survival in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial.

Authors:  Nirat Beohar; Veronica V Sansing; Andrew M Davis; V S Srinivas; Tarek Helmy; Andrew D Althouse; Stephen B Thomas; Maria Mori Brooks
Journal:  Am J Cardiol       Date:  2013-08-01       Impact factor: 2.778

8.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

Review 9.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.